

KaloBios Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jan-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

| | |
|--------------------------------|----|
| Company Overview..... | 5 |
| Company Profile..... | 6 |
| Product Portfolio Summary..... | 7 |
| Product Portfolio Drugs..... | 11 |

[Return to Table of Contents](#)

KaloBios Pharmaceuticals Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|---|
| Company Name | KaloBios Pharmaceuticals Inc |
| Parent Company Name | KaloBios Pharmaceuticals Inc |
| Website | http://kalobios.com/ |
| Country | US |
| Number of Drugs in Active Development | 3 |
| Number of Inactive Drugs | 1 |
| Number of Patents as Owner | 16 |
| Number of Patents as Third Party | 2 |
| Number of Deals | 14 |
| Key Indications | Asthma,Cancer,Rheumatoid arthritis,Chronic myelocytic leukemia,Cystic fibrosis,Hematological neoplasm,Inflammatory disease,Pseudomonas infection,Unidentified indication,Chronic obstructive pulmonary disease,Pseudomonas aeruginosa infection |
| Key Target-based Actions | Epha3 tyrosine kinase receptor inhibitor,Immunoglobulin G1 modulator,Immunoglobulin kappa modulator,GM-CSF receptor antagonist,GM-CSF ligand inhibitor,VEGF receptor antagonist,ACE inhibitor,Acetylcholinesterase inhibitor,Beta amyloid antagonist,Complement C3 inhibitor,Complement Factor B inhibitor,DHFR inhibitor,EGF like module receptor antagonist,EPHA3 gene inhibitor,EPHA3 gene modulator,Epha3 tyrosine kinase receptor modulator,Epha3 tyrosine kinase receptor stimulator,Folate antagonist,Immunoglobulin G agonist,NMDA receptor antagonist,PcrV protein type III inhibitor,Prokineticin receptor-2 antagonist |
| Key Technologies | Monoclonal antibody humanized,Biological therapeutic,Infusion,Intravenous formulation,Antibody,Drug combination,Monoclonal antibody,Antibody fragment,Antibody polyclonal,Chimeric antibody |

COMPANY PROFILE

SUMMARY

KaloBios Pharmaceuticals is engaged in the development of patient-targeted, first-in-class monoclonal antibodies designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Such uses include de novo discovery of high-affinity human antibodies, as well as optimization of antibodies and other therapeutic proteins. KaloBios has the capability to discover, engineer and develop clinically relevant antibodies, protein therapeutics, and small molecules, but is also actively seeking genomics, biotechnology and pharmaceutical collaborators to use its technologies, and to partner and co-develop its drugs.

ACQUISITIONS AND SPIN-OFFS

In January 2004, KaloBios merged with Celscia Therapeutics. The resulting company was named KaloBios.

LICENSING AGREEMENTS

In October 2008, BioWa licensed non-exclusive rights to its POLLITIGENT platform to KaloBios Pharmaceuticals for enhancing the antibody-dependent cellular cytotoxicity of select KaloBios therapeutic antibodies.

In April 2007, Novartis non-exclusively licensed KaloBios' Humaneering technology for the development of human antibodies. KaloBios had previously humanized three antibodies for Novartis, and would generate three more. In May 2006, KaloBios humanized an antibody against an undisclosed target for Novartis. The companies also extended their agreement. KaloBios received research and success fees and would receive milestones and royalties.

In June 2004, KaloBios licensed a murine monoclonal antibody for the potential treatment of Pseudomonas aeruginosa infection from the Medical College of Wisconsin and the University of California San Francisco.

FINANCIAL

[Return to Table of Contents](#)



In October 2012, the company was planning an IPO of its stock.

In September 2012, the company had completed a \$10 million long-term debt financing with MidCap Financial SBIC and also the company have the option to borrow an additional \$5 million by the end of the second quarter of 2013.

By September 2012, the company had raised gross proceeds of \$20.25 million from the closing of series E financing round.

In September 2008, KaloBios raised \$20 million from a series D financing round. In December 2008, the company raised a further \$12 million from the financing.

In July 2007, KaloBios completed a \$20 million series C financing round.

In March 2005, KaloBios completed a \$20 million series B financing. Proceeds from the financing would be used to build a clinical development team and to progress two lead antibodies into clinical evaluation.


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


| Indication | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Musculoskeletal disease | 1 | 1 | 2 |
| Respiratory disease | 2 | 0 | 2 |
| Neoplasm | 2 | 0 | 2 |

[Return to Table of Contents](#)

| | | | |
|--------------------------|---|---|---|
| Inflammatory disease | 1 | 1 | 2 |
| Immune disorder | 1 | 1 | 2 |
| Hematological disease | 2 | 0 | 2 |
| Degeneration | 0 | 1 | 1 |
| Infectious disease | 1 | 0 | 1 |
| Neurological disease | 0 | 1 | 1 |
| Dermatological disease | 0 | 1 | 1 |
| Gastrointestinal disease | 1 | 0 | 1 |
| Unidentified indication | 1 | 0 | 1 |

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 2 Clinical | 2 |
| Phase 1 Clinical | 1 |
| No Development Reported | 1 |

[Return to Table of Contents](#)

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 2 | 0 | 1 | 0 | 3 |
| Drug - Funding | 4 | 0 | 0 | 0 | 4 |
| Drug - Early Research/Development | 0 | 0 | 3 | 0 | 3 |
| Drug - Development/Commercialization License | 1 | 0 | 3 | 0 | 4 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|--------------------------|---------|-----|
| Respiratory disease | 2 | 5 |
| Immune disorder | 1 | 5 |
| Inflammatory disease | 1 | 5 |
| Musculoskeletal disease | 0 | 3 |
| Hematological disease | 0 | 2 |
| Gastrointestinal disease | 1 | 2 |
| Dermatological disease | 0 | 1 |
| Neoplasm | 0 | 1 |
| Infectious disease | 0 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 2 | 4 |
| Phase 1 | 0 | 6 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



PATENTS *

| Indication | As Owner | As Third Party | Total |
|---------------------------|----------|----------------|-------|
| Immune disorder | 5 | 1 | 6 |
| Neoplasm | 7 | 0 | 7 |
| Genetic disorder | 1 | 0 | 1 |
| Metabolic disorder | 2 | 0 | 2 |
| Neurological disease | 4 | 0 | 4 |
| Prophylaxis | 1 | 0 | 1 |
| Degeneration | 2 | 0 | 2 |
| Andrology | 1 | 0 | 1 |
| Cardiovascular disease | 4 | 1 | 5 |
| Endocrine disease | 2 | 0 | 2 |
| Genitourinary disease | 1 | 0 | 1 |
| Dermatological disease | 3 | 0 | 3 |
| Gastrointestinal disease | 4 | 0 | 4 |
| Growth disorder | 1 | 0 | 1 |
| Hematological disease | 4 | 0 | 4 |
| Musculoskeletal disease | 3 | 0 | 3 |
| Respiratory disease | 4 | 1 | 5 |
| Infectious disease | 5 | 0 | 5 |
| Injury | 1 | 0 | 1 |
| Unidentified indication | 1 | 0 | 1 |
| Inflammatory disease | 4 | 1 | 5 |
| Gynecology and obstetrics | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

KB-003

| | |
|-----------------------------|--|
| Drug Name | KB-003 |
| Key Synonyms | |
| Originator Company | Ludwig Institute for Cancer Research |
| Active Companies | KaloBios Pharmaceuticals Inc |
| Inactive Companies | Ludwig Institute for Cancer Research |
| Highest Status | Phase 2 Clinical |
| Active Indications | Chronic myelocytic leukemia, Rheumatoid arthritis, Asthma, Inflammatory disease, Unidentified indication |
| Target-based Actions | Immunoglobulin kappa modulator, Immunoglobulin G1 modulator, GM-CSF ligand inhibitor |
| Other Actions | Anti-inflammatory, Anticancer monoclonal antibody |
| Technologies | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 11-Dec-2012 |

KB-001

| | |
|-----------------------------|---|
| Drug Name | KB-001 |
| Key Synonyms | |
| Originator Company | University of California San Francisco |
| Active Companies | KaloBios Pharmaceuticals Inc, Sanofi Pasteur |
| Inactive Companies | University of California San Francisco |
| Highest Status | Phase 2 Clinical |
| Active Indications | Cystic fibrosis, Pseudomonas infection |
| Target-based Actions | PcrV protein type III inhibitor |
| Other Actions | Antibacterial |
| Technologies | Monoclonal antibody humanized, PEGylated formulation, Intravenous formulation, Biological therapeutic |
| Last Change Date | 26-Jun-2012 |

[Return to Table of Contents](#)

KB-004

| | |
|-----------------------------|---|
| Drug Name | KB-004 |
| Key Synonyms | |
| Originator Company | KaloBios Pharmaceuticals Inc |
| Active Companies | KaloBios Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Cancer, Hematological neoplasm |
| Target-based Actions | Epha3 tyrosine kinase receptor inhibitor, Immunoglobulin kappa modulator, Immunoglobulin G1 modulator |
| Other Actions | Anticancer monoclonal antibody, Anticancer protein kinase inhibitor |
| Technologies | Monoclonal antibody humanized, Intravenous formulation, Infusion, Biological therapeutic |
| Last Change Date | 04-Jan-2013 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)